Meeting
2020 Genitourinary Cancers Symposium
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: Analysis of the STAR TOR registry.
Authors
Michael Moran
Pfizer Pharma GmbH, Berlin, Germany
Michael Moran , Marcus Hubbe , Michael Rink , Lothar Bergmann , Arne Strauss , Stephan Bernhardt , Marianne Schmid , Martin Boegemann , Katrin Schlack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 628)
Abstract #
628
Poster Bd #
D14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells
Poster
2024 ASCO Genitourinary Cancers Symposium
Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.
First Author: Hyejee Ohm
Poster
2023 ASCO Annual Meeting
Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.
First Author: Dvir Aran
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah